Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;24(10):1287-1298.
doi: 10.1007/s11912-022-01278-0. Epub 2022 May 16.

Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer

Varsha Tulpule  1 , Gareth J Morrison  1 , Mary Falcone  2 , David I Quinn  1   2 , Amir Goldkorn  3   4   5
Affiliations
Review

Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer

Varsha Tulpule et al. Curr Oncol Rep. 2022 Oct.

Abstract

Purpose of review: The field of liquid biopsies is constantly evolving through novel technologies. This review outlines current data on liquid biopsies and application to clinical management of metastatic prostate cancer.

Recent findings: To date, there are three platforms with FDA approval for use in the setting of metastatic prostate cancer and others which have been clinically validated. There is substantial evidence supporting the use of circulating tumor cell (CTC) enumeration to guide prognosis in metastatic castration-resistant prostate cancer (mCRPC). Additional evidence supports targeted sequencing of CTC and cell-free DNA (cfDNA) to guide androgren-directed therapy, identify candidates for treatment with PARP inhibitors, and monitor development of resistance. As a real-time and minimally invasive approach, utilization of liquid biopsies has the potential to drastically impact the treatment of metastatic prostate cancer and improve overall survival. With further clinical validation, additional liquid biopsy is likely to enter standard clinical practice.

Keywords: Cell-free DNA; Circulating tumor DNA; Circulating tumor cells; Liquid biopsy; Metastatic prostate cancer.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Proposed model for incorporation of liquid biopsies into clinical management of metastatic prostate cancer.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021;71(1):7–33. doi: 10.3322/caac.21654. - DOI - PubMed
    1. Chowdhury S, Bjartell A, Lumen N, Maroto P, Paiss T, Gomez-Veiga F, et al. Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry. Target Oncol 2020;15(3):301–15. doi: 10.1007/s11523-020-00720-2. - DOI - PMC - PubMed
    1. Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014;32(30):3436–48. doi: 10.1200/JCO.2013.54.8404. - DOI - PMC - PubMed
    1. National Comprehensive Cancer Network. Prostate Cancer (Version 1.2022) http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed October 4, 2021.
    1. Teo MY, Rathkopf DE, Kantoff P. Treatment of Advanced Prostate Cancer. Annu Rev Med 2019;70:479–99. doi: 10.1146/annurev-med-051517-011947. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances